The FDA announced on Sept. 5, 2025, that Apotex Corp. is recalling Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution due to a lack of assurance of sterility caused by improper bottle sealing. Owners should contact the company for a refund.
How to tell if you have it
- Brand: Apotex
- Product: Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, Rx Only, Sterile
- Sizes: 5 mL and 10 mL
- NDC: 60505-0589-1 (5 mL), 60505-0589-2 (10 mL)
- Lot codes: VE0614, VE0616
- Expiration date: 12/2025
- UPC: 00360505058914
The hazard
The recall addresses potential sterility concerns resulting from improper bottle sealing that led to atypical weight loss in the product. The FDA classified this as a Class II recall involving 151,034 bottles distributed nationwide.
Context
GovInfoNow's records show Apotex Corp. has 24 other recalls on record since June 14, 2007. Recent similar recalls include the Paroxetine 37.5mg recall due to dissolution failure (Sept. 23, 2026) and the Paxil CR 37.5mg Tablets recall for failed stability testing (Aug. 13, 2026). Other recent recalls of similar products include the Clear Eyes Eye Drops Recall: Lack of Sterility Risk (Sept. 15, 2026), the K.C. Pharmaceuticals Ultra Lubricating Eye Drops Recall: Lack of Sterility Risk (March 3, 2026), and the K.C. Pharmaceuticals Sterile Eye Drops AC Recall: Lack of Sterility Risk (March 3, 2026).